

Part VI: Summary of the risk management plan

Summary of risk management plan for Levosimendan EQL Pharma

This is a summary of the risk management plan (RMP) for Levosimendan EQL Pharma. The RMP details important risks of Levosimendan EQL Pharma, how these risks can be minimised, and how more information will be obtained about Levosimendan EQL Pharma's risks and uncertainties (missing information).

Levosimendan EQL Pharma 's summary of product characteristics (SmPC) and its package leaflet give essential information to healthcare professionals and patients on how Levosimendan EQL Pharma should be used.

I. The medicine and what it is used for

Levosimendan EQL Pharma is authorised for the short-term treatment of acutely decompensated severe chronic heart failure (ADHF) in situations where conventional therapy is not sufficient, and in cases where inotropic support is considered appropriate (see SmPC for the full indication). It contains Levosimendan as the active substance and it is a concentrate for solution for infusion. The infusion is for intravenous use only and can be administered by the peripheral or central route.

II. Risks associated with the medicine and activities to minimise or further characterise the risks

Important risks of Levosimendan EQL Pharma, together with measures to minimise such risks and the proposed studies for learning more about Levosimendan EQL Pharma 's risks, are outlined below.

Measures to minimise the risks identified for medicinal products can be:

- Specific information, such as warnings, precautions, and advice on correct use, in the package leaflet and SmPC addressed to patients and healthcare professionals;
- Important advice on the medicine's packaging;
- The authorised pack size — the amount of medicine in a pack is chosen so to ensure that the medicine is used correctly;
- The medicine's legal status — the way a medicine is supplied to the patient (e.g. with or without prescription) can help to minimise its risks.

Together, these measures constitute *routine risk minimisation* measures.

In addition to these measures, information about adverse reactions is collected continuously and regularly analysed so that immediate action can be taken as necessary. These measures constitute *routine pharmacovigilance activities*.

If important information that may affect the safe use of Levosimendan EQL Pharma is not yet available, it is listed under 'missing information' below.

II.A List of important risks and missing information

Important risks of Levosimendan EQL Pharma are risks that need special risk management activities to further investigate or minimise the risk, so that the medicinal product can be safely administered. Important risks can be regarded as identified or potential. Identified risks are concerns for which there is sufficient proof of a link with the use of Levosimendan EQL Pharma. Potential risks are concerns for which an association with the use of this medicine is possible based on available data, but this association has not been established yet and needs further evaluation. Missing information refers to information on the safety of the medicinal product that is currently missing and needs to be collected (e.g. on the long-term use of the medicine);

List of important risks and missing information	
Important identified risks	<ul style="list-style-type: none">• None
Important potential risks	<ul style="list-style-type: none">• None
Missing information	<ul style="list-style-type: none">• None

II.B Summary of important risks

The safety information in the proposed Product Information is aligned to the reference medicinal product.

II.C Post-authorisation development plan

II.C.1 Studies which are conditions of the marketing authorisation

There are no studies which are conditions of the marketing authorisation or specific obligation of Levosimendan EQL Pharma.

II.C.2 Other studies in post-authorisation development plan

There are no studies required for Levosimendan EQL Pharma